27 results about "Myeloma cell" patented technology

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention discloses a method for inducing cell copper death based on GK921 and application of the GK921, and relates to the technical field of biological medicine. The invention discloses a brand new function of inducing copper death by a known compound GK921 for the first time, and provides a brand new strategy for solving the problems of drug resistance and relapse of multiple myeloma. According to the method, target cells are treated with an effective amount of GK921, expression of copper ion transporter ATP7A in the cells is specifically reduced, copper ions are accumulated, and then typical copper death events such as iron-sulfur cluster protein reduction and DLAT protein oligomerization are caused. Experiments show that the GK921 can efficiently inhibit the activity of multiple myeloma cell lines and primary cells, and the IC50 value and the low toxicity to normal cells show excellent selectivity. On the basis, GK921 can be used for preparing a pharmaceutical composition for inducing copper death, and particularly has an important application prospect in treatment of multiple myeloma.

Provided are human therapeutic compositions including a compound comprising a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compound is a reaction product of an aldehyde and a harmine component. The compositions exhibit anti-cancer properties, particularly against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

The application provides an abnormal prothrombin detection kit and application thereof, and relates to the technical field of in-vitro detection.The application provides a kit for abnormal prothrombin detection, which comprises an abnormal prothrombin antibody, wherein the abnormal prothrombin antibody is derived from a hybridoma cell strain 7E8-4-4-1 of fusion of myeloma cells and mouse B cells, and the hybridoma cell strain 7E8-4-4-1 is preserved in the China General Microbiological Culture Collection Center on October 28, 2025, with a preservation number of CGMCC No.46709.The kit has a large detection range, a small lower limit of detection and high accuracy, and has great application potential in the detection of abnormal prothrombin.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

A blocking monoclonal antibody screening method based on a porcine PD-1 / PD-L1 monoclonal antibody and a heterologous Fc fusion protein comprises the following steps: (a) preparing a porcine PD-1 or PD-L1 extracellular region recombinant protein; (b) immunizing mice by using the recombinant protein to obtain immune spleen cells; (c) fusing the immune spleen cells with myeloma cells to obtain hybridoma cells; (d) screening and subcloning a hybridoma cell strain capable of secreting an anti-porcine PD-1 or PD-L1 antibody; (e) preparing a porcine PD-L1-rabbit Fc fusion protein; and (f) evaluating the blocking effect of the monoclonal antibody on PD-1 / PD-L1 binding by using the PD-L1-rabbit Fc fusion protein through flow cytometry.

This invention relates to the field of traditional Chinese medicine composition technology, and particularly to an oral traditional Chinese medicine composition for treating multiple myeloma and its preparation method. It comprises the following components in parts by weight: Bupleurum chinense 10-12 parts, Cyperus rotundus 8-10 parts, Curcuma longa 8-10 parts, Oroxylum indicum 5-6 parts, Angelica sinensis 8-10 parts, Paeonia lactiflora 8-10 parts, Atractylodes macrocephala 10-12 parts, Poria cocos 10-12 parts, Codonopsis pilosula 8-10 parts, Glycyrrhiza uralensis (processed) 5-6 parts, Agrimonia pilosa 6-8 parts, Bambusa textilis 8-10 parts, Mentha haplocalyx 4-6 parts, and Zingiber officinale 4-6 parts. The composition provided by this invention not only directly inhibits the growth of myeloma cells, but also comprehensively improves the survival prognosis of model animals by regulating liver and spleen function, improving immune status, and reducing phlegm-heat and blood stasis. It provides a stable, safe, and easily promoted oral traditional Chinese medicine preparation for the clinical treatment of multiple myeloma.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the pharmaceutical composition containing CD4+ CTL as an active ingredient. The CD4+ CTL according to the present invention performs a cytotoxic function of directly attacking and killing myeloma cells, thereby extending the progression-free survival of transplant-ineligible myeloma patients, and thus can contribute to increasing the survival rate of the patients. In addition, by using NKG2D+ CD4+ CTL as a biomarker for predicting the prognosis of myeloma patients, it is possible to analyze the CD4+ CTL status of individual patients and thereby establish customized treatment strategies. In addition, by increasing the cytotoxicity of NKG2D+ CD4+ CTL through a specific cytokine treatment, it is possible to more effectively prevent or treat cancer.

The application discloses a myeloma microscopic cell image cancer cell counting method and belongs to the technical field of medical image processing. In order to solve the problem of realizing automatic and accurate counting of myeloma cells, the application collects myeloma multi-channel microscopic image data for adaptive preprocessing, fuses noise suppression and convolution enhancement, obtains pixel gray value of the preprocessed myeloma multi-channel microscopic image, then carries out rough segmentation of cancer cells based on edge constraint to obtain a rough segmentation mask of the image, then carries out deep feature extraction to obtain the deep feature of the pixel of the preprocessed myeloma multi-channel microscopic image, then calculates the average deep feature of the cells, then combines Bayesian prior correction to calculate the probability of the cancer cells through MLP deep modeling, and finally, the application verifies the cancer cell counting result through correlation coefficient calibration combined with clinical prior constraint to obtain the final myeloma cancer cell counting result. The application provides technical support for standardization and normalization of myeloma diagnosis.

The invention discloses an interferon regulatory factor 4 (IRF4) inhibitor as shown in a formula (1) and a preparation method thereof, and a target product is prepared by taking dinorhydrin as a raw material through reactions such as TBS protection, 4, 4-dimethylation, TBS protection removal, oxidation, esterification, reduction, iodination, cyano substitution, Wittig, hydrolysis, esterification, amidation, condensation and the like. The invention further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM), and further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM). The compound can selectively inhibit the multiplication capacity of IRF4 high-expression myeloma cells, and has a good application prospect in treatment of IRF4 high-expression tumors such as multiple myeloma and lymphoma.

The present application relates to the technical field of biological medicine, and particularly relates to an anti-Aβ 42 Monoclonal antibody, preparation method and application. The present application adopts Aβ 42 protein of human origin as an immunogen to immunize BALB / c mice, extracts B lymphocytes of the spleen of the mice after successful immunization, fuses the B lymphocytes with mouse myeloma cells SP2 / 0 through cell fusion technology, and obtains hybridoma cell strains stably secreting anti-Aβ 42 monoclonal antibody after three rounds of subclone screening, so as to obtain anti-Aβ 42 monoclonal antibody; the anti-Aβ 42 monoclonal antibody can specifically combine with Aβ 42 protein, and can be used for immunological detection, has a broad market prospect, and can have important clinical significance for further development of biological monitoring technology and therapeutic drugs taking Aβ 42 as a target.

The invention discloses an anti-p53R175H / HLA-A 02: 01 monoclonal antibody, a hybridoma cell strain S2-C33 for preparing the monoclonal antibody as well as a preparation method and application of the monoclonal antibody. The preparation method of the hybridoma cell strain comprises the following steps: immunizing a BALB / c mouse by taking human p53R175H / HLA-A 02: 01 recombinant protein as an immunogen to prepare an immunized mouse; taking splenocytes of the immunized mouse, and fusing the splenocytes with the SP2 / 0 myeloma cells to prepare fusion cells; screening monoclonal antibody positive fusion cells capable of secreting a compound specifically combined with p53R175H / HLA-A 02: 01 from the fusion cells, wherein the monoclonal antibody positive fusion cells are the hybridoma cell strain. The monoclonal antibody secreted by the hybridoma cell strain can be specifically combined with p53R175H / HLA-A 02: 01 presented on the surface of cancer cells, and the specificity is relatively high.

The application discloses a kind of screening and anti-myeloma application of targeting c-Maf small molecule inhibitor, especially provide the application of sorafenib or glimepiride in preparation anti-myeloma drug.Aspect.The application discloses a kind of method for screening targeting c-Maf small molecule inhibitor, it includes the steps based on molecular virtual screening docking.It is found that potential compound glimepiride and sorafenib can inhibit the activity of c-Maf by the method of the application through virtual screening, molecular dynamics (MD) simulation, molecular mechanics and MM / GBSA free energy calculation and experimental analysis, both can induce the cycle stagnation and cell apoptosis of myeloma cell.The method of the application can screen more targeting c-Maf small molecule inhibitor, it is also helpful to further structure optimization based on sorafenib and glimepiride in the future, and design c-Maf small molecule inhibitor with better activity.

This invention provides a benzothiadiazine compound that inhibits histone deacetylases, its preparation method, and its applications. The general structural formula is shown in Formula (I), or an isomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug thereof. The benzothiadiazine compound of this invention has a novel structure and, as an inhibitor of histone deacetylases HDAC6 and HDAC1, can effectively inhibit the proliferation of K562 (human chronic myeloid leukemia cells) and NCI-H929 (human myeloma cells). It exhibits low cytotoxicity to normal cells and low potential cardiac risk, and holds promise as a highly effective and low-toxicity antitumor therapeutic agent.

The application of mitoxantrone in inducing IRF4 protein degradation through autophagy-lysosome pathway belongs to the field of biological medicine. Mitoxantrone can specifically bind to IRF4 protein and significantly reduce the level of IRF4 protein. Mitoxantrone mainly binds to the DNA binding domain of IRF4, shortens the half-life of IRF4 protein, and promotes its degradation through the autophagy-lysosome pathway rather than the proteasome pathway. Mitoxantrone can interact with IRF4 protein and autophagy receptor p62 at the same time, promote the formation of IRF4 and p62 complex, enhance the ubiquitination modification of IRF4 and recruit it to the autophagy degradation pathway, thereby playing the role of molecular glue. Mitoxantrone treatment can inhibit the transcriptional activation function mediated by IRF4, down-regulate the expression of its downstream target genes, inhibit the proliferation of multiple myeloma cells and tumor growth, and provide a new technical approach for the development of anti-tumor drugs targeting transcription factors.

The invention discloses a myeloma microscopic cell image cancer cell counting method, and belongs to the technical field of medical image processing. The aim of achieving automatic and accurate counting of myeloma cells is achieved. According to the method, myeloma multi-channel microscopic image data is collected for self-adaptive preprocessing, noise suppression and convolution enhancement are fused to obtain a pixel gray value of a preprocessed myeloma multi-channel microscopic image, then cancer cell coarse segmentation based on edge constraint is carried out to obtain a coarse segmentation mask of the image, then depth feature extraction is carried out to obtain a coarse segmentation mask of the image; the method comprises the following steps: preprocessing a myeloma multichannel microscopic image to obtain depth features of pixels of the preprocessed myeloma multichannel microscopic image, then calculating an average depth feature of cells, then calculating the probability of cancer cells according to the obtained average depth feature of the cells through MLP depth modeling in combination with Bayesian prior correction, and then verifying through correlation coefficient calibration in combination with clinical prior constraints. The myeloma cancer cell counting method provides technical support for standardization and normalization of myeloma diagnosis.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody for HPV16 type E7 protein detection and application of the monoclonal antibody. E7 protein serving as an antigen and a Freund's complete adjuvant are mixed, then a mouse is subjected to primary immunization, then the E7 protein and a Freund's incomplete adjuvant are mixed, then the mouse is subjected to enhanced immunization, and the HPV16 type E7 protein detection monoclonal antibody is obtained. The monoclonal antibody for detecting the HPV16 type E7 protein is prepared by taking mouse splenocytes and myeloma cells to be fused to prepare hybridoma cells, then performing clone detection on the hybridoma cells to screen the hybridoma cells aiming at the specificity of the HPV16 type E7 protein, and finally obtaining the monoclonal antibody for detecting the HPV16 type E7 protein. According to the present invention, the HPV16 type E7 antigen detection kit is developed by using the immunochromatography method, and the kit has advantages of high sensitivity, strong specificity, simple operation and fast detection speed, and can be used for rapid screening diagnosis and illness state monitoring of HPV16.

The invention discloses a supramolecular polypeptide-drug coupled prodrug nano material for treating multiple myeloma as well as a preparation method and application of the supramolecular polypeptide-drug coupled prodrug nano material. According to the nano material, hyaluronic acid modified by beta-cyclodextrin is taken as a skeleton, and a melphalan-dexamethasone double-drug coupling compound coupled with an adamantane modified GFLG short peptide connexon is loaded through a supramolecular host-guest effect. The nano material has good stability and drug entrapment capacity under physiological conditions, and can realize quick-response drug release under the condition of simulating an enzymatic environment in myeloma cells. The nano material can realize efficient cellular uptake and specific drug activated release, so that proliferation of multiple myeloma cells is inhibited, and a new strategy for delivery of the multiple myeloma nano drug with a synergistic treatment effect is provided.

The application discloses a chicken MTRF1L protein monoclonal antibody and application thereof, and belongs to the technical field of biotechnology.The MTRF1L recombinant protein is used for immunizing animals, a sensitized B cell with the ability of secreting specific antibodies and a myeloma cell with unlimited reproduction capacity are fused into a B cell hybridoma through a hybridoma technology, and a chicken MTRF1L protein monoclonal antibody is obtained through screening.The application screens a high-quality nucleotide coding sequence of the MTRF1L gene through bioinformatics analysis, and uses the nucleotide coding sequence as an antigen to immunize BABE mice, a sensitized B cell with the ability of secreting specific MTRF1L antibodies and a myeloma cell with unlimited reproduction capacity are fused into a B cell hybridoma through a hybridoma technology, and a positive hybridoma cell is obtained through screening, and the cell supernatant is used for Western Blot and indirect immunofluorescence detection, and it is found that the monoclonal antibody has good specificity and high sensitivity, which lays a foundation for detection of the MTRF1L protein and research on pathological mechanisms of virus infection diseases.

The present application provides the anti-multiple myeloma activity and application of rotigotine. Experimental results show that rotigotine is relocated to the Tudor domain of the polycomb-like protein family PHF19 protein, and PHF19 is a significant marker of multiple myeloma. Rotigotine has good selectivity to non-polycomb-like proteins, effectively inhibits the viability of multiple myeloma cells MM1.S, and inhibits tumor growth in tumor-bearing mice, showing that rotigotine can become an anti-multiple myeloma drug.

The present application relates to the technical field of nanobody, in particular to anti-FcRH5 nanobody and its application. The present application provides a kind of anti-FcRH5 nanobody with high affinity and specificity, which is based on the single domain heavy chain variable region structure of camelid origin, with the advantages of small molecular weight, high stability, strong tissue penetration, easy to be engineered and the like. The nanobody specifically recognizes and binds to the target point highly expressed and stably expressed on the surface of multiple myeloma cells through its complementarity determining region. The nanobody of the present application can be used as a core recognition element to construct a variety of therapeutic or diagnostic tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes. The technical scheme can solve the technical problem that there is a lack of high-quality, functionally clear anti-FcRH5 antibody in the prior art. The nanobody of the present application has significant clinical transformation and industrialization advantages, and promotes the treatment of multiple myeloma to multiple target points.

The invention discloses a preparation method of an anti-human hepatitis B surface antigen monoclonal antibody. The preparation method comprises the following steps: step 1, extracting a human hepatitis B surface antigen HBsAg; 2, selecting an experimental animal, wherein the experimental animal is a mouse; 3, animal immunization is conducted on the mouse, purified antigen HBsAg is injected for immunization, and injection positions are subcutaneous and abdominal cavities; step 4, continuing to carry out second immunization and third immunization by using the same dose of antigen and the same method; step 5, using the same dosage of antigen and the same method to carry out booster immunization before cell fusion; 6, taking out the spleen of the mouse after three days of boosted immunization, preparing a cell suspension, preparing myeloma cells, and fusing the cell suspension and the myeloma cells into hybridoma cells; 7, screening hybridoma cells, and culturing and cloning the screened hybridoma cells; and 8, preparing ascites, and purifying the ascites to obtain the monoclonal antibody. Compared with the prior art, the invention has the advantage of providing the preparation method of the anti-human hepatitis B surface antigen monoclonal antibody with higher purity.

The invention relates to the technical field of biological medicines, in particular to an anti-Abeta42 monoclonal antibody for relieving AD cognitive behaviors and a preparation method thereof. The preparation method comprises the following steps: immunizing a BALB / c mouse by adopting human-derived Abeta42 protein as an immunogen, extracting spleen B lymphocytes of the mouse after successful immunization, fusing the B lymphocytes with myeloma cells SP2 / 0 of the mouse through a cell fusion technology, and carrying out three rounds of subcloning screening to obtain the hybridoma cell strain capable of stably secreting the anti-Abeta42 monoclonal antibody. And thus, the anti-Abeta42 monoclonal antibody is obtained. The anti-Abeta42 monoclonal antibody can be specifically combined with Abeta42 protein, can relieve AD cognitive behaviors, can be used for immunological detection, has a wide market prospect, and also has important clinical significance for further development of biological monitoring technologies and therapeutic drugs taking Abeta42 as a target spot.

The invention relates to application of retinol compounds and carfilzomib in preparation of drugs for treating multiple myeloma, and belongs to the technical field of antitumor drugs. Aiming at the problem of drug resistance in treatment of multiple myeloma, the invention provides a technical scheme of drug combination. The retinol compound is preferably synthetic retinol WYC-209, the retinol compound can enhance the sensitivity of carfilzomib for treating multiple myeloma, and the action mechanism is that WYC-209 aggravates endoplasmic reticulum stress of multiple myeloma cells and destroys an endoplasmic reticulum structure. The combined treatment scheme can inhibit proliferation of multiple myeloma cells, induce cell apoptosis, reduce tumor load, inhibit bone marrow infiltration of tumor cells and improve the long-term survival rate of mice. The invention further provides a pharmaceutical composition containing WYC-209 and carfilzomib, the mass ratio of WYC-209 to carfilzomib is (0.01-3000): 1, and the pharmaceutical composition can be prepared into a solution or suspension and is suitable for treating first-diagnosis high-risk multiple myeloma or recurrent / refractory multiple myeloma.

The present invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell maturation antigen (BCMA). The present invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR, and methods for destroying multiple myeloma cells.